Biogen Inc.
BIIB
Rank in Stocks
#702
Biogen Inc. is a leading biotechnology firm dedicated to the discovery,... Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.
Share Price
$238.55
Market Cap
$35.25B
Change (1 day)
2.17%
Change (1 year)
62.69%
Country
US
Trade Biogen Inc. (BIIB)
Category
Healthcare
P/E ratio for Biogen Inc. (BIIB)
P/E ratio as of October 2026 TTM: 40.99
According to Biogen Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 40.99. At the end of 2024 the company had a P/E ratio of 13.65.
P/E ratio history for Biogen Inc. from 2000 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 40.99 | 105.37% |
| 2025 | 19.96 | 46.23% |
| 2024 | 13.65 | -57.67% |
| 2023 | 32.25 | 144.20% |
| 2022 | 13.21 | -42.55% |
| 2021 | 22.99 | 133.43% |
| 2020 | 9.85 | 4.45% |
| 2019 | 9.43 | -32.25% |
| 2018 | 13.92 | -47.83% |
| 2017 | 26.67 | 59.47% |
| 2016 | 16.73 | -16.06% |
| 2015 | 19.93 | -27.12% |
| 2014 | 27.34 | -23.13% |
| 2013 | 35.57 | 40.93% |
| 2012 | 25.24 | 16.78% |
| 2011 | 21.61 | 28.41% |
| 2010 | 16.83 | 6.19% |
| 2009 | 15.85 | -10.87% |
| 2008 | 17.78 | -36.89% |
| 2007 | 28.17 | -63.21% |
| 2006 | 76.57 | -19.02% |
| 2005 | 94.55 | -89.37% |
| 2004 | 889.50 | -6,456.00% |
| 2003 | -13.99 | -116.02% |
| 2002 | 87.35 | -11.39% |
| 2001 | 98.58 | 16.62% |
| 2000 | 84.53 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 40.53 | -1.13% |
US
|
|
| 38.50 | -6.09% |
US
|
|
| 79.88 | 94.86% |
US
|
|
| 116.96 | 185.32% |
US
|
|
| 22.25 | -45.72% |
CH
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.